The August issue of The American Journal of Gastroenterology includes clinical discussions of diet-associated NAFLD risk and increased risk of mortality from COVID-19 among PPI users. In addition, this issue features clinical research and reviews on IBS, gender barriers for CRC screening, hepatitis C, eosinophilic esophagitis, and more.
A combination of remdesivir, a drug currently approved in the United States for treating COVID-19 patients, and repurposed drugs for hepatitis C virus (HCV) was 10 times more effective at inhibiting SARS-CoV-2, the virus that causes COVID-19.
When combined with drugs currently used to treat hepatitis C, the antiviral remdesivir is 10 times more effective in treating cells infected with SARS-CoV-2, the virus that causes COVID-19.
The AIDS Clinical Trials Group (ACTG), the largest global HIV research network, will present four oral and 20 scientific spotlight sessions at the Conference on Retroviruses and Opportunistic Infections (CROI 2021) held virtually, March 6-10.
Study finds that in a diverse, global patient population, a minimal monitoring (MINMON) approach to hepatitis C treatment was safe and achieved comparable sustained virologic response (SVR) to current standard of care.
Data from a new study presented this week at The Liver Meeting Digital Experience® – held by the American Association for the Study of Liver Diseases (AASLD)– found that among pregnant women with hepatitis C virus (HCV), more than 25 percent were initially diagnosed during pregnancy screenings, which supports prenatal care as an important opportunity to screen for HCV in women. However, the study also found that less than one third of infants receive appropriate HCV testing, a significant care gap.
While screening guidelines for hepatitis C previously targeted baby boomers, experts say more universal testing guidelines should be followed for early detection and better outcomes.
Critics of the universal hepatitis C screening argue that it’s wasteful to test pregnant women for a disease that can’t be immediately treated, but results of a small phase I clinical trial suggest otherwise: pregnancy could be an excellent time to diagnose and cure hepatitis C infection.
A study explored racial inequalities in death from liver cancer before and after the introduction of lifesaving drugs for hepatitis C. Results showed that from 1979 to 1998, racial inequalities in mortality from liver cancer in the U.S. were declining. But, from 1998 to 2016, of the 16,770 deaths from liver cancer among blacks, the excess relative to whites increased from 27.8 percent to 45.4 percent. Concurrently, racial inequalities in death decreased for major risk factors for liver cancer, such as alcohol and diabetes.
A risk factor for liver disease, cirrhosis and liver cancer, hepatitis C virus (HCV) infection is linked to the deaths of more U.S. patients than the next 60 infectious disease combined – including HIV and tuberculosis. Worryingly, its incidence is…
H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act passed by the House of Representatives today introduces critically needed and significant steps to reduce costs and improve access to life-saving therapies for conditions including HIV and hepatitis C. Importantly, the legislation also brings essential resources to combat antibiotic resistance, find and develop new infection fighting drugs and bring them to market. The balanced approach of this legislation will serve patients and public health.
HCVguidelines.org — a website developed by the American Association for the Study of Liver Diseases and the Infectious Diseases Society of America to provide up-to-date guidance on the management of hepatitis C — was recently revised to reflect important developments in the identification and management of chronic hepatitis C (HCV)
A new study by researchers at the University of Montreal shows close to 172,000 Canadians injected drugs in 2016, up from 130,000 just five years earlier, but support varies.
Data from a new study presented this week at The Liver Meeting® – held by the American Association for the Study of Liver Diseases – found that hepatitis C virus-related hepatocellular carcinoma (HCC) patients who achieved sustained virologic response (SVR) – denoting an undetectable level of HCV virus – with any oral direct-acting antiviral (DAA) had over 60-70 percent improvement in five-year survival.